Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 02 Jun 2025 | Florika Fink-Hooijer Director-General | Pandemic preparedness | — |
| 02 Jun 2025 | Florika Fink-Hooijer Director-General | Pandemic preparedness | SRC |
| 03 Nov 2022 | Daphne Von Buxhoeveden Cabinet member | Videoconference with Moderna CEO on future of mRNA platform; ongoing cooperation on the management of the pandemic | — |
| 03 Nov 2022 | Daphne Von Buxhoeveden Cabinet member | Videoconference with Moderna CEO on future of mRNA platform; ongoing cooperation on the management of the pandemic | SRC |
| 26 Nov 2021 | Ursula von der Leyen President | Meeting with CEO of Moderna | — |
| 26 Nov 2021 | Ursula von der Leyen President | Meeting with CEO of Moderna | SRC |
| 10 Apr 2021 | Thierry Breton Commissioner | Vaccine production and deliveries | SRC |
| 10 Apr 2021 | Thierry Breton Commissioner | Vaccine production and deliveries | — |
| 31 Jan 2021 | Ursula von der Leyen President | Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements | — |
| 31 Jan 2021 | Ursula von der Leyen President | Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements | SRC |
Mission & Goals
Moderna is a biotechnology company focused on developing and commercialising medicines and vaccines based on messenger RNA (mRNA) technology across multiple therapeutic areas including infections diseases, oncology and rare disease. The company's mission is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
EU Legislative Interests
Moderna's interest relates to legislative and policy initiatives affecting pharmaceutical innovation, public health, access, intellectual property, trade, manufacturing and supply chain resilience and initiatives relating to environmental, sustainability and digital. These include in particular: - Revision of the EU General Pharmaceutical Legislation - Critical Medicines Act - Implementation of Regulation 2021/2282 on Health Technology Assessment - Public health/biosafety preparedness and response frameworks (e.g. HERA) - EU Biotechnology Act (1 & 2) - EU Vaccines Strategy - Respiratory vaccines policies & procurement mechanisms - Pharmaceutical Strategy for Europe - Global Health Resilience Initiative - MDR - EU Health Dataspace - AI Act - Industry Accelerator Act
Communication Activities
Participation in high-level events Scientific publications and other articles in relation to mRNA technology
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
VE - Vaccines Europe (https://www.vaccineseurope.eu) Eucope - European Confederation of Pharmaceutical Entrepreneurs AISBL (www.eucope.org) IFPMA - International Federation of PHarmaceutical Manufacturers & Associations (www.ifpma.org) BIO - Biotechnology Innovation Organization (www.bio.org)
Organisation Members
N/A
Additional Information
The estimate of annual costs related to activities covered by the register includes personal costs, the relevant percentage of trade associations membership fees and relevant costs for intermediaries, as declared above.